These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 18798087)
1. Recent developments in drug delivery to prolong allograft survival in lung transplant patients. Watts AB; Williams RO; Peters JI Drug Dev Ind Pharm; 2009 Mar; 35(3):259-71. PubMed ID: 18798087 [TBL] [Abstract][Full Text] [Related]
2. Sublingual tacrolimus for immunosuppression in lung transplantation: a potentially important therapeutic option in cystic fibrosis. Reams BD; Palmer SM Am J Respir Med; 2002; 1(2):91-8. PubMed ID: 14720063 [TBL] [Abstract][Full Text] [Related]
3. Tacrolimus: a further update of its use in the management of organ transplantation. Scott LJ; McKeage K; Keam SJ; Plosker GL Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696 [TBL] [Abstract][Full Text] [Related]
4. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Tönshoff B; Höcker B Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497 [TBL] [Abstract][Full Text] [Related]
5. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. Staatz CE; Tett SE Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096 [TBL] [Abstract][Full Text] [Related]
6. Evolution to twice daily bolus intravenous tacrolimus: optimizing efficacy and safety of calcineurin inhibitor delivery early post lung transplant. Snell GI; Ivulich S; Mitchell L; Westall GP; Levvey BJ Ann Transplant; 2013 Aug; 18():399-407. PubMed ID: 23921892 [TBL] [Abstract][Full Text] [Related]
7. Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival. Gallagher HM; Sarwar G; Tse T; Sladden TM; Hii E; Yerkovich ST; Hopkins PM; Chambers DC J Heart Lung Transplant; 2015 Nov; 34(11):1442-8. PubMed ID: 26186804 [TBL] [Abstract][Full Text] [Related]
11. Once-daily oral administration of cyclosporine in a lung transplant patient with a history of renal toxicity of calcineurin inhibitors. Matsuda Y; Chen F; Miyata H; Date H Interact Cardiovasc Thorac Surg; 2014 Jul; 19(1):171-3. PubMed ID: 24659549 [TBL] [Abstract][Full Text] [Related]
12. Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss? He X; Johnston A Transplant Proc; 2004 Jun; 36(5):1321-6. PubMed ID: 15251323 [TBL] [Abstract][Full Text] [Related]
13. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960 [TBL] [Abstract][Full Text] [Related]
14. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766 [TBL] [Abstract][Full Text] [Related]
15. The effect of maintenance immunosuppression medication on the change in kidney allograft function. Gill JS; Tonelli M; Mix CH; Johnson N; Pereira BJ Kidney Int; 2004 Feb; 65(2):692-9. PubMed ID: 14717943 [TBL] [Abstract][Full Text] [Related]
16. Inhaled delivery of aerosolized cyclosporine. Corcoran TE Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1119-27. PubMed ID: 16997418 [TBL] [Abstract][Full Text] [Related]
20. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Noble S; Markham A Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]